406 related articles for article (PubMed ID: 37480423)
1. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.
Suzuki Y; Ishiguro S; Shimada H; Ohgami M; Suzuki M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):633-638. PubMed ID: 38148336
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.
Ferjani H; El Arem A; Bouraoui A; Achour A; Abid S; Bacha H; Boussema-Ayed I
J Physiol Biochem; 2016 Jun; 72(2):133-44. PubMed ID: 26746208
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
[TBL] [Abstract][Full Text] [Related]
7. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus.
Canivet C; Böhler T; Galvani S; Therville N; Salvayre R; Durand D; Thomsen M; Rostaing L; Kamar N
Transplant Proc; 2008 Dec; 40(10):3422-3. PubMed ID: 19100403
[TBL] [Abstract][Full Text] [Related]
8. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.
Wiesner RH; Shorr JS; Steffen BJ; Chu AH; Gordon RD; Lake JR
Liver Transpl; 2005 Jul; 11(7):750-759. PubMed ID: 15973716
[TBL] [Abstract][Full Text] [Related]
10. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.
Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T
Intern Med; 2020 Dec; 59(23):3055-3059. PubMed ID: 32727989
[TBL] [Abstract][Full Text] [Related]
11. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
15. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
16. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.
Jain AB; Hamad I; Rakela J; Dodson F; Kramer D; Demetris J; McMichael J; Starzl TE; Fung JJ
Transplantation; 1998 Nov; 66(10):1395-8. PubMed ID: 9846530
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
Eckhoff DE; McGuire BM; Frenette LR; Contreras JL; Hudson SL; Bynon JS
Transplantation; 1998 Jan; 65(2):180-7. PubMed ID: 9458011
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits.
Mehra MR; Uber PA; Park MH; Ventura HO; Scott RL
Transplant Proc; 2004 Dec; 36(10):3152-5. PubMed ID: 15686716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
